Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M169Revenue $M18.1Net Margin (%)-85.4Z-Score1.8
Enterprise Value $M146EPS $-0.3Operating Margin %-112.4F-Score3
P/E(ttm))0Cash Flow Per Share $-0.0Pre-tax Margin (%)-114.1Higher ROA y-yY
Price/Book2.410-y EBITDA Growth Rate %0Quick Ratio4.0Cash flow > EarningsY
Price/Sales9.25-y EBITDA Growth Rate %104Current Ratio5.0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-16.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-33.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M61.9ROI % (ttm)-45.5Gross Margin Increase y-yN

Gurus Latest Trades with NEPT

Number of guru portfolios checked: 56.

No Entry found!

NEPT is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NEPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Haywood, George Weaver10% Security Holder 2013-10-24Buy26,677$3.12-27.56 view
Haywood, George Weaver10% Security Holder 2013-10-23Buy7,596$3.05-25.9 view
Haywood, George Weaver10% Security Holder 2013-10-22Sell30,000$3.2-29.38 view
Haywood, George Weaver10% Security Holder 2013-10-22Buy30,000$3.21-29.6 view
Haywood, George Weaver10% Security Holder 2013-10-17Buy30,000$3.16-28.48 view
Simard, EricSenior Officer 2013-10-11Sell15,000$3.68-38.59 view
Haywood, George Weaver10% Security Holder 2013-10-03Buy82,396$3.62-37.57 view
Haywood, George Weaver10% Security Holder 2013-10-02Buy74,604$3.48-35.06 view
Simard, EricSenior Officer 2013-10-02Sell9,200$3.71-39.08 view
Haywood, George Weaver10% Security Holder 2013-08-16Buy11,000$3.66-38.25 view

Press Releases about NEPT :

    Quarterly/Annual Reports about NEPT:

      News about NEPT:

      Articles On GuruFocus.com
      What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

      More From Other Websites
      Acasti Announces First Quarter Results Jul 15 2014
      Neptune Announces First Quarter Results Jul 15 2014
      Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials Jul 09 2014
      Neptune to Hold Conference Call to Discuss First Quarter Results Jul 08 2014
      Neptune Receives Composition Patent in Australia Jun 23 2014
      NeuroBioPharm Reports Results of Annual General Meeting Jun 20 2014
      Neptune Reports Results of Annual and Special Meeting Jun 20 2014
      Neptune Sherbrooke Plant to Resume Production Jun 13 2014
      Has Enzymotec Been Over-Punished? Jun 09 2014
      NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Financials Jun 06 2014
      Neptune, Acasti and NeuroBioPharm Announce Litigation Regarding its Former Chief Executive Officer May 30 2014
      High option volume stocks May 28 2014
      Neptune Technologies appoints Andre Godin as interim CEO May 23 2014
      Neptune, Acasti and NeuroBioPharm Announce Appointment of Interim CEO May 23 2014
      Neptune Technologies reports Q4 revenue $3.67M, consensus $7.08M May 21 2014
      Neptune Announces Fourth Quarter and Fiscal Year Results May 21 2014
      NeuroBioPharm Announces Resignation of Chief Financial Officer May 20 2014
      Neptune Announces Proposed Director Nominees for Its Upcoming Annual General Meeting May 16 2014
      Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal Year Results May 13 2014
      Neptune Technologies says CSST report attributes some responsibility to company May 08 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide